Cancer Archives – DHbriefs

Wefight

Dusan Belic — Wed, 26 Jul 2023 04:15:49 +0000

Wefight has created an AI-powered Virtual Companion called Vik to support every patient with cancer and chronic diseases. To that end, Vik empowers and engages patients by answering their questions 24/7 and providing them with the right information at the right time throughout their healthcare journey. At the same time, Vik collects real-world data and generates real-world evidence to enhance patient care — enabling Wefight to create fit-for-purpose solutions in collaboration with medical experts and patients. Beyond its Virtual Companion (Vik), Wefight’s offering includes Vik Studies (helps enhance patient understanding with tailored studies and direct access to invisible data), Vik PROM (an app specifically designed to capture ePROs with high-quality standards), and MedVik (an online platform that allows healthcare professionals to follow up on their patients after they’ve left the medical facilities). The company has offices in France (Montpellier and Paris) and Germany (Berlin).

The post Wefight appeared first on DHbriefs.

hema.to

Dusan Belic — Tue, 04 Jul 2023 19:42:21 +0000

hema.to provides fully automated, AI-powered diagnosis recommendations for blood cancer from flow cytometry data. This, in turn, increases efficiency and quality for hemato-oncology labs using hema.to’s cloud-based platform. In order to use it, diagnosticians upload flow data files, and the solution provides them with clinical indications and diagnostic recommendations, which follow expert consensus.

The post hema.to appeared first on DHbriefs.

Tagworks Pharmaceuticals

Dusan Belic — Wed, 28 Jun 2023 06:56:42 +0000

Tagworks Pharmaceuticals is a precision therapy company and a pioneer of the Click-to-Release approach. Leveraging its patent-protected technology platform, it aims to create a new standard of care for patients suffering from severe diseases, including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72 — a clinically-validated, pan-carcinoma target that so far has remained out of reach of current ADC therapies. Tagworks’ technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index.

The post Tagworks Pharmaceuticals appeared first on DHbriefs.

Tribun Health

Dusan Belic — Wed, 21 Jun 2023 04:34:10 +0000

Formerly called Tribvn Healthcare, Tribun Health powers the digital transformation of cancer diagnosis by designing innovative solutions. These solutions enable the management, analysis, and sharing of cellular images for both diagnostic laboratories and pharmaceutical/biotech companies. They use AI to support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. Also, Tribun’s solutions implement full web tools to support customers in their telepathology, teaching or multi-centric clinical validation activities.

The post Tribun Health appeared first on DHbriefs.

Dark Blue Therapeutics

Dusan Belic — Tue, 13 Jun 2023 05:13:17 +0000

Dark Blue Therapeutics is an innovative drug discovery biotechnology company leveraging ground-breaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology, Dark Blue Therapeutics matches its precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs — delivering medicines that transform the outcomes for cancer patients. It works across various biological mechanisms to identify and pursue only cancer targets with the highest transformative potential.

The post Dark Blue Therapeutics appeared first on DHbriefs.

Proxygen

Dusan Belic — Sun, 04 Jun 2023 20:49:05 +0000

Proxygen develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. It is focused on particular small molecules called “molecular glue degraders,” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.

The post Proxygen appeared first on DHbriefs.

Orakl

Dusan Belic — Sun, 04 Jun 2023 20:20:08 +0000

Orakl leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With its platform, the company partners with oncology players to identify relevant targets and deliver new drugs, faster.

The post Orakl appeared first on DHbriefs.

Ariceum Therapeutics

Dusan Belic — Sun, 04 Jun 2023 19:17:19 +0000

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of “Marie Curie” whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”) is an antagonist of the somatostatin type 2 (SST2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a “theranostic” pair for the combined diagnosis and targeted radionuclide treatment of these tumors.

The post Ariceum Therapeutics appeared first on DHbriefs.

T-knife Therapeutics

Dusan Belic — Sun, 04 Jun 2023 18:52:57 +0000

T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. In addition to Berlin, the company also has an office in San Francisco.

The post T-knife Therapeutics appeared first on DHbriefs.

Turbine

Dusan Belic — Sun, 04 Jun 2023 18:15:00 +0000

Turbine was founded to overcome the limitations of existing methods in identifying oncology treatments that truly benefit the patients who receive them by combining molecular biology and artificial intelligence. The company has developed and validated the Simulated Cell, a proprietary and cutting-edge platform that runs billions of simulations prior to ever initiating preclinical development guiding real-life experiments with invaluable biological insights. This improves the likelihood of success for truly novel therapies and allows existing assets to be optimally targeted to patients most likely to benefit from them. Simulations have already been validated from target discovery to patient stratification and life cycle management in collaborations with multiple big pharma companies. Turbine is now leveraging the Simulated Cell platform to develop its own stream of programs, pursuing multiple high unmet oncology needs. The company is also working with partners to extend its pipeline to various modalities and cancer mechanisms.

The post Turbine appeared first on DHbriefs.